Management Team

Mr Vivek D Samant , Founder & Managing Director.

Mr. Vivek D Samant, the founder of Yasham Group, has a 33 year  experience in International Business. Yasham is a 15 year old Group marketing a wide range of products on a global level and also serving the domestic industries by arranging specialty ingredients from international chemical manufacturers. Today we ably serve Pharma, Personal Care, Construction, Food, Agro, Veterinary segments. We supply novel ingredients for launching new drugs and formulations as well as new concepts in various industries. Leading a team of 40 motivated professionals, both technical and commercial, Mr. Samant is on the mission to do scientific research activity. He intends to partner with leading national and international research institutions on unmet medical needs in human and veterinary areas. Mr. Samant dreams of getting innovative diagnostic kits, biomarkers and ultramodern techniques in India and make it available to the rural population.


Email - viveksamant@yasham.in

Girish S. Kulkarni, MS Ph.D., Chief Scientific Officer.

Girish Kulkarni is a graduate from Mumbai University with 10 years of research experience in the US. He holds a Bachelor's degree in Pharmaceutical Sciences from Mumbai University, a Master's degree in Pharmacology/Toxicology from St. John's University, New York, a Ph.D. in Toxicology from University of Maryland School Of Medicine, Baltimore, and has completed a postdoctoral fellowship in Neuroscience and In vivo Pharmacology, from University of Maryland Medical Center, Baltimore, USA. Dr. Kulkarni's work spans across various aspects of drug discovery and development cycle – including pilot study design, development, testing, analysis, protocol generation, troubleshooting and post-studies support. For 10 years, he has worked extensively on different projects in the field of general pharmacology, pulmonary biology, neurosciences, in vivo pharmacology and mechanistic toxicology. Dr Kulkarni is based at our Mumbai Head Office and oversees our ongoing projects. He will be leading the organization for the future. Apart from work, he finds pleasure in Hindustani and Carnatic music, going out on long drives and spending time with his extended family that includes Miffy, a German shepherd and Zulu, a Labrador retriever.

Email - gskulkarni@yasham.in

Gurudatt Dhareshwar, Ph.D,, Co-founder.

Gurudatt Dhareshwar, has over 30 years of leadership experience in technology transfer and process re-engineering for well-known companies including Ciba-Geigy (now Novartis), Searle India (associated G.D. Searle) and many Indian pharmaceutical and chemical companies. Gurudatt holds a Ph.D degree from Mumbai University and has completed post-doctoral research at the College of Pharmacy, Ohio State University, Columbus, Ohio. He has successfully accomplished technology transfer and scale-up of more than 35 to 40 pharmaceutical products including Metoprolol tartrate, Atorvastatine, Deltamethirine, Cyclosporine, Daunorubicin and Doxorubicin. Besides his specialization with technology transfer, Gurudatt has also conceptualized, planned and developed multiple research centers and multipurpose pharmaceutical manufacturing facilities for major pharmaceutical and chemical companies in India. Gurudatt has a strong grasp of the business methodologies within Indian pharmaceutical companies, is well connected with the leaders in the Pharmaceutical Industry in India and is focused on providing cost effective and business driven solutions.

Email - gdhareshwar@gmail.com

Prasad Gabbita, Ph.D., Vice President of Research and Development.

Prasad Gabbita, has lead the preclinical drug discovery, development and biomarker assay programs at P2D Bioscience and its predecessor companies for the past ten years. He brings 15 years of research experience and knowledge in neuroscience, toxicology, synthetic organic chemistry and drug formulation. Prasad received his doctoral and post-doctoral training at the University of Kentucky College of Medicine and Sanders Brown Center on Aging in Lexington. He has been the recipient of nearly $ 2 mn in research funding for drug and diagnostic development from several agencies including the Michael J. Fox Foundation, the Alzheimer's Drug Discovery Foundation and the National Institutes of Health. Prasad has authored about 20 peer-reviewed scientific publications and book chapters.

Email - pgabbita@p2dinc.com